Gain Therapeutics shares surge 23.56% intraday after GT-02287 shows positive Phase 1b Parkinson's trial results with reduced CSF glucosylsphingosine and 79% participant continuation rate.

Gain Therapeutics surged 23.56% intraday, announcing that GT-02287 in its Parkinson’s Phase 1b trial demonstrated a significant reduction in ceramides in cerebrospinal fluid for the first time, with the drug well-tolerated in 21 participants and 79% opting to continue in a 9-month extension study.